AZACITIDINE AUXILIA süstesuspensiooni pulber Естонія - естонська - Ravimiamet

azacitidine auxilia süstesuspensiooni pulber

auxilia pharma oÜ - asatsitidiin - süstesuspensiooni pulber - 100mg 1tk

Kerendia Європейський Союз - естонська - EMA (European Medicines Agency)

kerendia

bayer ag - finerenone - renal insufficiency, chronic; diabetes mellitus, type 2 - reniini-angiotensiini süsteemi toimivad ained - kerendia is indicated for the treatment of chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes in adults.

Scemblix Європейський Союз - естонська - EMA (European Medicines Agency)

scemblix

novartis europharm limited - asciminib hydrochloride - leukeemia, müelogeenne, krooniline, bcr-abl positiivne - antineoplastilised ained - scemblix is indicated for the treatment of adult patients with philadelphia chromosome positive chronic myeloid leukaemia in chronic phase (ph+ cml cp) previously treated with two or more tyrosine kinase inhibitors (see section 5.

Dapagliflozin Viatris Європейський Союз - естонська - EMA (European Medicines Agency)

dapagliflozin viatris

viatris limited - dapagliflozin - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - diabeetis kasutatavad ravimid - type 2 diabetes mellitusdapagliflozin viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 ja 5. heart failuredapagliflozin viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. chronic kidney diseasedapagliflozin viatris is indicated in adults for the treatment of chronic kidney disease.

Vafseo Європейський Союз - естонська - EMA (European Medicines Agency)

vafseo

akebia europe limited - vadadustat - renal insufficiency, chronic; anemia - antianemilised preparaadid - vafseo is indicated for the treatment of symptomatic anaemia associated with chronic kidney disease (ckd) in adults on chronic maintenance dialysis.

Lyfnua Європейський Союз - естонська - EMA (European Medicines Agency)

lyfnua

merck sharp & dohme b.v. - gefapixant - cough - köha ja külmad preparaadid - lyfnua is indicated in adults for the treatment of refractory or unexplained chronic cough.

AZACITIDINE ICG FARMA süstesuspensiooni pulber Естонія - естонська - Ravimiamet

azacitidine icg farma süstesuspensiooni pulber

icg farma uab - asatsitidiin - süstesuspensiooni pulber - 25mg 1ml 6ml 1tk; 25mg 1ml 4ml 1tk

Luveris Європейський Союз - естонська - EMA (European Medicines Agency)

luveris

merck europe b.v.  - lutropiin alfa - ovulation induction; infertility, female - suguhormoonid ja genitaalsüsteemi, - luveris koos folliikuleid stimuleeriva hormooni (fsh) preparaadiga on soovitatav folliikulite arengu stimuleerimiseks raske luteiniseeriva hormooni (lh) ja fsh puudulikkusega naistel. kliinilistes uuringutes, need patsiendid olid määratletud on endogeensed seerumi lh tase.

MENOPUR süstelahus pen-süstlis Естонія - естонська - Ravimiamet

menopur süstelahus pen-süstlis

ferring gmbh - menopausaalne humaangonadotropiin - süstelahus pen-süstlis - 600rÜ 1tk

RIVAROXABAN ORION õhukese polümeerikattega tablett Естонія - естонська - Ravimiamet

rivaroxaban orion õhukese polümeerikattega tablett

orion corporation - rivaroksabaan - õhukese polümeerikattega tablett - 20mg 14tk; 20mg 100tk; 20mg 28tk; 20mg 98tk; 20mg 10tk